Akademik Veri Yönetim Sistemi
6. EBAT Eurasia Biochemical Approaches & Technologies , Tokat, Türkiye, 24 - 27 Ekim 2024, ss.53
Cancer remains a major global health problem, and according to 2020 World Health Organization, it is estimated that more than 18 million people worldwide will be affected by cancer, tragically 9.6 million will die and it is worryingly predicted that this number will almost double by 2040.1 Cancer continues to fascinate the scientific community as one of the most perplexing diseases to afflict human populations. Its diversity of types, unpredictable course and challenging treatment options make it an enduring puzzle that warrants relentless investigation.2 Recently, the phenolic Schiff base ligand has attracted great attention in the field of medicinal chemistry due to its versatile behavior and biological significance and they can play an important role in designing new chemotherapeutic compounds.3 Schiff base-based metallo-drugs are being investigated to develop new anticancer and chemotherapy agents, since anticancer targets are different, heterocyclic Schiff bases can be structurally modified to obtain the desired molecule targeting a specific disease. In the 20th century, the world's first anticancer drug cisplatin has been discovered, which brings the medicinal inorganic chemistry in the frontline area of research. Taking advantage of the improved pharmaceutical effect of Schiff base compounds, combined anticancer drugs can be synthesized via a Schiff base reaction. In this study, firstly, a ligand was synthesized by the reaction of 4-methoxysalicylaldehyde and an aminophenol derivate. And the complexes of this ligand were prepared with some transition metals. These compounds were characterized using elemental, thermal and spectroscopic techniques.4 The cytotoxic effects of these synthesized compounds were then tested on the breast cancer MCF-7 and lung cancer A-549 cell lines. Afterwards, the apoptotic effect of the most active compound was examined by flow cytometry analysis.